Autoimmune Disease Treatment Market boosted by Growing Investment in Pharmaceutical indusrty | Size, Share and Global Revenue Analysis by 2026
According to the National Institute of Health (NIH), there were approximately 23.5 million American’s suffering from an autoimmune disease in 2012. Moreover, the Department of Health and Human Services, in 2017, reported that autoimmune disease (AID) is ranked first in the top ten list of popular health topics. Autoimmune disease can lead to various complications in a different part of the body, such as heart, brain, kidneys, glands, and nerves. The increasing rate of autoimmune disease is mainly owing to genetic and environmental factors, such as dietary components, toxic chemicals, and infections is a prime factor fueling market growth. Autoimmune diseases include inflammatory bowel diseases (IBD), rheumatic arthritis (RA), multiple sclerosis (MS), celiac disease (CD), hepatitis, autoimmune thyroiditis (AT), systemic lupus erythematous (SLE) and type 1 diabetes (IDDM). According to the International Journal of Celiac Disease, in 2015, stated that the environmental factors are strongly related to cause autoimmune diseases, which include infections, ecology, and nutrition.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/895
AID is difficult to diagnose because of a lack of basic knowledge about disease patterns, to identify treatments, and design clinical trials. Increasing awareness among the population about autoimmune diseases and its complications is expected to contribute towards the growth of the autoimmune disease treatment market.
By Disease Types
By Drug Type
- Anti-Inflammatory Drugs
- Nonsteroidal anti-inflammatory drugs
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/895
Advanced approaches for the treatment of AID is projected to favor the market growth of autoimmune disease treatment
Increasing innovation in the treatment of AID is projected to foster the autoimmune disease treatment market. For instance, researchers at the Perelman School of Medicine in 2016, found a way to target a specific subset of antibody, which is responsible for the activation of pemphigus vulgaris (PV) autoimmune disease. The researchers designed chimeric autoantibody receptor therapy (CAART) that can be used to treat this disease without harming the healthy immune system.
Moreover, researchers at the Cumming School of Medicine in 2016, developed a new class of Nano-medicine to treat diseases, specifically type 1 diabetes, multiple sclerosis, and rheumatoid arthritis without compromising immunity. This Nano-medicine is currently being developed at Parvus Therapeutics, Inc., and is funded by Innovate Calgary.
Moreover, advancements in research are offering new treatment of autoimmune diseases. For instance, StemGenex Medical group registered with the National Institute of Health (NIH) in June 2017, to provide stem cell therapy for five different diseases, which include multiple sclerosis, Parkinson’s disease, Rheumatoid arthritis, chronic obstructive pulmonary disease, and osteoarthritis. Moreover, the American Autoimmune Related Diseases Association, Inc. (AARDA) in 2016 conducted a study on the potential cause of AID and its treatment by using genetic elements (reteroelements) as LINE-1. However, the findings of the studies are not confirmed yet.
According to the American Autoimmune Related Diseases Association (AARDA), in 2017, approximately 50 million Americans are suffering from autoimmune disease. High prevalence of autoimmune diseases demands for new treatment approach, which may include biomarkers, stem cell research, and genetic research. Biological agents such as TNF agents, monoclonal antibodies, tissue and organ engineering procedure, gene-based delivery system, modulators of the immune system, and cell-based treatments are under evaluation for the treatment of AID.
Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/895
Growing awareness regarding autoimmune diseases and rising demand for the therapeutic approaches is projected to favor the growth of the autoimmune disease treatment market.
Government and biopharmaceutical are investing in research and development activities in order to develop novel drugs and therapies for autoimmune disease treatment, which is expected to be the major driving factor for the growth of the autoimmune disease treatment market in near future.
According to the Centers for Disease Control and Prevention (CDC), the prevalence of arthritis from 2013 to 2015, was estimated at 54.4 million in the U.S. adults (22.7%) and by 2040, it is expected to be 78 million (26%). As per the CDC, prevalence has been increasing more rapidly in middle-low income economies, hence this is expected to foster the growth of autoimmune disease treatment market. According to a case report by BioMed Central, 2015, growing chronic infections and disorder, for instance, SLE associated with pregnancy can lead to maternal, obstetric, and fetal problems, in turn fueling the growth of autoimmune disease treatment market in near future. On the downside, the high cost of the therapy is expected to hamper the growth of AID treatment market.
Key players operating the global autoimmune disease treatment market include Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc. AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb.
Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/autoimmune-disease-treatment-market-895
Table of Content
Global Autoimmune Disease Treatment Market Research Report
Section 1: Global Autoimmune Disease Treatment Industry Overview
Section 2: Global Economic Impact on Autoimmune Disease Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Autoimmune Disease Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Autoimmune Disease Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire